The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -5,891 | -11,863 |
| Allowance for credit losses (recoveries) | 0 | 217 |
| Depreciation and amortization | 66 | 499 |
| Share-based compensation | 2,022 | 4,177 |
| Payment-in-kind interest | 318 | 172 |
| Amortization of debt issuance costs and original issue discounts | 39 | 21 |
| Amortization of lease right of use assets, net of accretion in lease liabilities | 360 | 461 |
| Accounts receivable | -260 | -237 |
| Inventory, net | 498 | -482 |
| Prepaid expenses and other current assets | 560 | 136 |
| Other assets | 192 | 0 |
| Accounts payable and accrued expenses | 693 | -1,944 |
| Lease liabilities | -245 | -471 |
| Contract liabilities | 507 | -576 |
| Net cash flows from operating activities | -3,121 | -8,724 |
| Purchases of property and equipment | 199 | 274 |
| Net cash flows from investing activities | -199 | -274 |
| Proceeds from offering of common stock, net of offering costs | 0 | 3,263 |
| Proceeds from issuance of note payable, net of financing costs and discount | 0 | 28,653 |
| Repayment of 2020 senior secured convertible note | 0 | - |
| Proceeds from stock option exercises | 0 | 49 |
| Payments for taxes related to net share settlement of equity awards | 0 | 1,661 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 311 |
| Net cash flows from financing activities | 0 | 30,615 |
| Net change in cash, cash equivalents and restricted cash | -3,320 | 21,617 |
| Cash and cash equivalents at beginning of period | 20,104 | - |
| Cash and cash equivalents at end of period | 38,401 | - |
ClearPoint Neuro, Inc. (CLPT)
ClearPoint Neuro, Inc. (CLPT)